Regeneron's rare immune disorder therapy meets main goal of late-stage trial-August 2024-www.financetom.com

Regeneron's rare immune disorder therapy meets main goal of late-stage trial

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Regeneron's rare immune disorder therapy meets main goal of late-stage trial

Aug 26, 2025 4:28 AM

Aug 26 (Reuters) - Regeneron Pharmaceuticals ( REGN )

said on Tuesday its experimental therapy for treating patients

with a rare immune disorder has met the main goal of a

late-stage study.

Previous page： MPS shares slide further as Mediobanca board meets to discuss bid Next page： Ubisoft to close UK site and restructure three others, affecting 185 staff

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

MPS shares slide further as Mediobanca board meets to discuss bid

Jan 28, 2025

MILAN (Reuters) - Shares in Monte dei Paschi fell further on Tuesday as the board of Mediobanca gathered to discuss a surprise bid by the smaller rival, the latest move in a series of takeover tussles rattling Italian banking. MPS announced a 13.3-billion euro ($13.9 billion) buyout bid for Mediobanca on Friday but the value of its all-share offer has...

Ubisoft to close UK site and restructure three others, affecting 185 staff

Jan 28, 2025

(Reuters) - France's largest video game maker Ubisoft will close its Leamington site in Britain and restructure operations at Ubisoft Düsseldorf, Ubisoft Stockholm and Ubisoft Reflections, impacting 185 employees, it said on Tuesday, confirming earlier media reports. The decision is a part of efforts to prioritize projects and reduce costs to ensure long-term stability at Ubisoft, it said. Ubisoft has...

SAP Q4 Non-IFRS Earnings, Revenue Increase

Jan 28, 2025

03:57 AM EST, 01/28/2025 (MT Newswires) -- SAP (SAP) reported Q4 non-IFRS earnings from continuing operations Tuesday of 1.40 euros ($1.46) per share, up from 1.12 euros a year earlier. Analysts polled by FactSet expected 1.34 euros. Revenue for the quarter ended Dec. 31 was 9.38 billion euros, up from 8.47 billion euros a year earlier. Analysts surveyed by FactSet...

Alibaba's Tsai-backed firm buys 12% of Italian luxury sneaker maker Golden Goose

Jan 28, 2025

MILAN, Jan 28 (Reuters) - Blue Pool, a Hong Kong-based investment firm backed by Alibaba ( BABA ) co-founder Joe Tsai, has bought a 12% stake in Italian luxury sneaker maker Golden Goose, the Venice-based brand said on Tuesday. The investment comes after the maker of $600 a pair sneakers abruptly pulled plans for a stock market listing last year....